Special Issue "Optimization of Tuberculosis Drugs and Treatment Strategies to End Tuberculosis (TB)"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".
Deadline for manuscript submissions: 1 November 2023 | Viewed by 247
Special Issue Editors
2. Westhead Hospital, West Mead, NSW 2145, Australia
3. Sydney Institute of Infectious Diseases, The University of Sydney, Camperdown, NSW 2006, Australia
Interests: tuberculosis; pharmacokinetics; pharmacodynamics; therapeutic drug monitoring; clinical trials; personalized dosing
2. Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, 10176 Solna, Sweden
Interests: tuberculosis; non-tuberculous mycobacteria; therapeutic drug monitoring and precision medicine; randomized controlled trials; minimum inhibitory concentrations; global health
2. Parramatta Chest Clinic, Western Sydney Local Health District, Sydney, NSW 2150, Australia
Interests: tuberculosis; respiratory diseases; evidence-based medicine; clinical trials; pulmonary rehabilitation
Dr. Andrew Burke
2. Faculty of Medicine, University of Queensland Centre for Clinical Research, Brisbane, QLD 4032, Australia
Interests: tuberculosis; pharmacokinetics; therapeutic drug monitoring; non-tuberculous mycobacteria; real world trials
Special Issue Information
Dear Colleagues,
Tuberculosis remains a global health tread. Significant progress has been made in the development of three new anti-TB drugs (bedaquiline, delamanid and pretomanid), and several other drugs are undergoing preclinical or clinical development. Strategies to develop shorter regimens using different dosing strategies of available TB drugs have been evaluated in large trials for preventative treatment, drug-susceptible TB as well as drug-resistant TB. In addition, in vitro and in vivo models as well as modeling and simulation have resulted in a better understanding of how treatment outcome can be improved. This Special Issue of Pharmaceutics is dedicated to presenting the latest evidence and information on new drugs and drug trials, drug dose optimization strategies and tools to support the management of TB treatment to ensure that it is safe and effective.
Prof. Dr. Jan-Willem Alffenaar
Dr. Lina Davies Forsman
Dr. Jin-Gun Cho
Dr. Andrew Burke
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tuberculosis
- drug development
- pharmacokinetics
- pharmacogenetics
- pharmacodynamics
- drug formulation
- clinical trials
- treatment outcome
